Commerce Bank purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) in the first quarter, according to its most recent filing with the SEC. The fund purchased 1,411 shares of the specialty pharmaceutical company’s stock, valued at approximately $206,000.
A number of other institutional investors have also made changes to their positions in the company. Treasurer of the State of North Carolina increased its holdings in shares of Jazz Pharmaceuticals by 1.5% in the 1st quarter. Treasurer of the State of North Carolina now owns 30,299 shares of the specialty pharmaceutical company’s stock valued at $4,434,000 after acquiring an additional 440 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in Jazz Pharmaceuticals by 155.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 47,433 shares of the specialty pharmaceutical company’s stock valued at $6,941,000 after purchasing an additional 28,839 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in Jazz Pharmaceuticals by 7.3% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 132,713 shares of the specialty pharmaceutical company’s stock valued at $19,420,000 after purchasing an additional 9,061 shares during the period. First National Bank of Omaha acquired a new position in Jazz Pharmaceuticals during the 1st quarter valued at approximately $5,661,000. Finally, AGF Management Ltd. boosted its position in Jazz Pharmaceuticals by 9.4% during the 1st quarter. AGF Management Ltd. now owns 23,561 shares of the specialty pharmaceutical company’s stock valued at $3,448,000 after purchasing an additional 2,022 shares during the period. 87.34% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. StockNews.com assumed coverage on Jazz Pharmaceuticals in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Bank of America boosted their price objective on Jazz Pharmaceuticals from $204.00 to $217.00 and gave the company a “buy” rating in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jazz Pharmaceuticals in a research report on Monday, July 10th. Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $203.00 to $201.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $226.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $212.00.
Insider Activity
In other news, EVP Neena M. Patil sold 1,600 shares of the business’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $127.98, for a total transaction of $204,768.00. Following the sale, the executive vice president now directly owns 32,826 shares of the company’s stock, valued at $4,201,071.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Neena M. Patil sold 1,600 shares of the business’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $127.98, for a total transaction of $204,768.00. Following the sale, the executive vice president now directly owns 32,826 shares of the company’s stock, valued at $4,201,071.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Renee D. Gala sold 6,000 shares of the business’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $131.75, for a total value of $790,500.00. Following the sale, the chief financial officer now directly owns 35,978 shares in the company, valued at $4,740,101.50. The disclosure for this sale can be found here. Insiders sold a total of 7,726 shares of company stock worth $1,011,386 over the last 90 days. 4.40% of the stock is currently owned by company insiders.
Jazz Pharmaceuticals Trading Up 1.6 %
Shares of Jazz Pharmaceuticals stock opened at $135.18 on Friday. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 1.71. The firm has a market cap of $8.67 billion, a price-to-earnings ratio of -53.22, a price-to-earnings-growth ratio of 1.03 and a beta of 0.73. The business has a fifty day simple moving average of $127.72 and a 200-day simple moving average of $137.22. Jazz Pharmaceuticals plc has a fifty-two week low of $120.64 and a fifty-two week high of $163.31.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Wednesday, May 10th. The specialty pharmaceutical company reported $3.20 earnings per share for the quarter, missing the consensus estimate of $3.58 by ($0.38). The firm had revenue of $892.81 million during the quarter, compared to analyst estimates of $898.11 million. Jazz Pharmaceuticals had a negative net margin of 4.18% and a positive return on equity of 24.72%. On average, equities analysts forecast that Jazz Pharmaceuticals plc will post 14.73 EPS for the current fiscal year.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.
Read More
- Five stocks we like better than Jazz Pharmaceuticals
- Video Game Stocks: How to Invest in Gaming
- Alibaba Explodes On Earnings, Inching Toward Triple Digit Prices
- Best Stocks Under $5.00
- Is It Time To Game The Roblox Market?
- What is a Low P/E Ratio and What Does it Tell Investors?
- 2 Cheap Stocks The Insiders Are Buying
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
